Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELGN-2112 in preterm infants with intestinal malabsorption
2021-004890-29Phase 3Active
- Sponsor
- Elgan Pharma
- Start
- Aug 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in intestinal malabsorption and Gastrointestinal immaturity comparing ELGN-2112 with Placebo (2 arms). Primary endpoint: Time to full enteral feeding. Started Aug 2022; status: active.
02
Drugs
elgn-gi
03
Conditions
intestinal malabsorptionGastrointestinal immaturity
Beyond the preview
Go deeper on 2021-004890-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004890-29.